HEOR, which refers to health economics and outcomes research, is a realm that is difficult to navigate due to its complexity, diverse nature, and numerous facets. Nevertheless, there is one key element that stands out: the patient is the most important element. With the purpose of shedding light on the influence that this trend has on healthcare systems around the world, this article investigates the increased emphasis on a patient-centric approach in HEOR.
At its core, HEOR is a multidisciplinary field that aims to enhance the accessibility, fairness, and efficiency of healthcare systems for patients. It requires an understanding and appreciation of factors that significantly affect patients’ health and their experiences. This field prioritises what truly matters to patients.
Rob Abbott, as the CEO and Executive Director of The International Society for Pharmacoeconomics and Outcomes Research (ISPOR), emphasised the importance of encouraging patient-focused work. He defined this as a collaborative and meaningful interaction between patients and researchers, occurring throughout the entire research process. During the decision-making process, patient experiences, values, and expertise serve as guiding principles. This helps to ensure that the data collected ultimately contributes to the improvement of patient outcomes.
Significant progress has been made in centering patients in HEOR, but much work remains. We need to boost the patient’s voice and create a more patient-focused decision-making process. However, integrating the patient throughout the entire healthcare journey presents significant challenges.Â
As ISPOR moves on with a new plan for the year 2024, it is making concerted efforts to establish HEOR as a crucial instrument for addressing the most significant challenges in the field of global healthcare. Affordability, the impact of the rapid digitalisation of health care, and the increased desire in providing comprehensive health care are some of these factors. The patient, on the other hand, is the focal point of each and every one of these issues.
When it comes to HEOR, the patient-centric approach focuses not only on improving people’s health but also on improving the patient experience in situations where their health has been compromised. In this context, it refers to making sure that the patients’ voices are heard and that their requirements are addressed.
🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.
A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.
#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1
💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?
A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.
Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.
#SyenzaNews #HealthEconomics #MarketAccess
🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?
This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.
Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!
#SyenzaNews #HealthEconomics #Innovation #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
